{
    "name": "tigecycline",
    "comment": "Rx",
    "other_names": [
        "Tygacil"
    ],
    "classes": [
        "Glycylcyclines"
    ],
    "source": "https://reference.medscape.com/drug/tygacil-tigecycline-342527",
    "pregnancy": {
        "common": [
            "May cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during second and third trimesters of pregnancy",
            "There are no available data on risk of major birth defects or miscarriage following use during pregnancy",
            "Advise patients of potential risk to fetus if drug is used during second or third trimester"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration of intravenous tigecycline in pregnant rats and rabbits during period of organogenesis was associated with reduction in fetal weights and an increased incidence of skeletal anomalies (delays in bone ossification) at exposures of 5 and 1 times the human exposure at recommended clinical dose in rats and rabbits, respectively"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk; however, tetracycline-class antibacterial drugs are present in breast milk",
            "Not known whether drug has an effect on breastfed infant or on milk production",
            "Drug has low oral bioavailability; therefore, infant exposure is expected to be low",
            "Drug is present in rat milk with little or no systemic exposure to drug in nursing pups as a result of exposure via maternal milk; when drug is present in animal milk, it is likely that the drug will be present in human milk",
            "Developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition",
            "Because of theoretical risk of dental discoloration and inhibition of bone growth, avoid breastfeeding if receiving therapy for longer than three weeks",
            "A lactating woman may consider interrupting breastfeeding and pumping and discarding breastmilk during administration of therapy and for 9 days (approximately 5 half-lives) after last dose in order to minimize drug exposure to a breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Increased mortality with use of tigecycline for FDA-approved indications, as well as for nonapproved indications, compared with other antibiotics",
                "Analysis from 10 clinical trials for FDA-approved uses (cSSSI, cIAI, CABP), including trials conducted after the drug was approved, showed a higher risk of death among patients receiving tigecycline, compared with other antibacterial drugs: 2.5% (66/2640) vs. 1.8% (48/2628), respectively; the adjusted risk difference for death was 0.6%, with a corresponding 95% confidence interval (0.0%, 1.2%)"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "FDA approved to treat complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP); it is not approved for treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia",
                "Increase in all-cause mortality reported in tigecycline treated patients versus comparator-treated patients; generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities; therapy should be reserved for use in situations when alternative treatments are not suitable",
                "A trial of patients with hospital-acquired, including ventilator-associated, pneumonia failed to demonstrate drug efficacy with lower cure rates in hospital-acquired pneumonia",
                "Anaphylactic reactions reported with nearly all antibacterial agents and may be life-threatening; tigecycline is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs",
                "Monotherapy should be avoided in patients with complicated intra-abdominal infections (cIAI) secondary to clinically apparent intestinal perforation",
                "The drug is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia)",
                "Prescribing therapy in absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
                "Increases in total bilirubin concentration, prothrombin time and transaminases reported in patients treated with tigecycline; caution in severe hepatic impairment (reduce dose); patients who develop abnormal liver function tests during therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy; hepatic dysfunction may occur after drug has been discontinued",
                "Hypofibrinogenemia reported; obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment ",
                "Avoid use in patients with known hypersensitivity to tetracyclines",
                "May have adverse effects similar to those of tetracyclines (eg, photosensitivity, pseudotumor cerebri, antianabolic action)",
                "Pancreatitis, including fatalities, reported; if pancreatitis suspected, consider stopping treatment; diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis; cases reported in patients without known risk factors for pancreatitis; patients usually improve after therapy discontinuation; consider cessation of treatment in cases suspected of having developed pancreatitis",
                "Increased mortality risk with use of IV tigecycline (see Black Box Warnings)",
                "May cause fetal harm when administered to a pregnant woman"
            ],
            "specific": [
                {
                    "type": "Tooth discoloration",
                    "description": [
                        "Use during tooth development may cause permanent discoloration of teeth; adverse reaction is more common during long-term use but has been observed following repeated short-term courses; enamel hypoplasia has also been reported",
                        "Use during second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth; tetracyclines form a stable calcium complex in any bone-forming tissue; a decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours; effect was shown to be reversible when therapy was discontinued; advise patient of potential risk to fetus if drug is used during second or third trimester of pregnancy"
                    ]
                },
                {
                    "type": "Clostridioides difficile",
                    "description": [
                        "Clostridioides difficile-associated diarrhea (CDAD) reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
                        "C. difficile produces toxins A and B which contribute to development of CDAD; hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy; CDAD must be considered in all patients who present with diarrhea following antibacterial drug use; careful medical history necessary since CDAD reported to occur over two months after administration of antibacterial agents",
                        "If CDAD suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued; appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "tigecycline decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "tigecycline, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "tigecycline decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "tigecycline decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "tigecycline will decrease the level or effect of bazedoxifene/conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "tigecycline will decrease the level or effect of conjugated estrogens by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide, tigecycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "tigecycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "tigecycline will decrease the level or effect of estradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "tigecycline will decrease the level or effect of estrogens conjugated synthetic by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estropipate",
            "description": {
                "common": "tigecycline will decrease the level or effect of estropipate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "tigecycline will decrease the level or effect of ethinylestradiol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "tigecycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "tigecycline will decrease the level or effect of mestranol by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, tigecycline.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "tigecycline decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "tigecycline will decrease the level or effect of balsalazide by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "biotin",
            "description": {
                "common": "tigecycline will decrease the level or effect of biotin by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "digoxin",
            "description": {
                "common": "tigecycline decreases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pantothenic acid",
            "description": {
                "common": "tigecycline will decrease the level or effect of pantothenic acid by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pyridoxine",
            "description": {
                "common": "tigecycline will decrease the level or effect of pyridoxine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pyridoxine (Antidote)",
            "description": {
                "common": "tigecycline will decrease the level or effect of pyridoxine (Antidote) by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiamine",
            "description": {
                "common": "tigecycline will decrease the level or effect of thiamine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "29.5"
        },
        {
            "name": "Vomiting",
            "percent": "19.7"
        },
        {
            "name": "Diarrhea",
            "percent": "12.7"
        },
        {
            "name": "Infection",
            "percent": "8.3"
        },
        {
            "name": "Fever",
            "percent": "7.1"
        },
        {
            "name": "Abd pain",
            "percent": "6.8"
        },
        {
            "name": "Headache",
            "percent": "5.9"
        },
        {
            "name": "HTN",
            "percent": "4.9"
        },
        {
            "name": "Anemia",
            "percent": "4.2"
        },
        {
            "name": "Dizziness",
            "percent": "3.5"
        },
        {
            "name": "Dyspnea",
            "percent": "2.9"
        },
        {
            "name": "Pruritus",
            "percent": "2.6"
        },
        {
            "name": "Rash",
            "percent": "2.4"
        },
        {
            "name": "Hypotension",
            "percent": "2.3"
        },
        {
            "name": "Insomnia",
            "percent": "2.3"
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "anaphylactoid reactions",
            "percent": null
        },
        {
            "name": "Acute pancreatitis",
            "percent": null
        },
        {
            "name": "Hypofibrinogenemia",
            "percent": null
        },
        {
            "name": "Hepatic cholestasis and jaundice",
            "percent": null
        },
        {
            "name": "Severe skin reactions",
            "percent": null
        },
        {
            "name": "including Stevens",
            "percent": null
        },
        {
            "name": "Johnson Syndrome",
            "percent": null
        },
        {
            "name": "Symptomatic hypoglycemia in patients with or without diabetes mellitus",
            "percent": null
        },
        {
            "name": "Prolonged activated partial thromboplastin time",
            "percent": null
        },
        {
            "name": "aPTT",
            "percent": null
        },
        {
            "name": "prolonged prothrombin time",
            "percent": null
        },
        {
            "name": "PT",
            "percent": null
        },
        {
            "name": "eosinophilia",
            "percent": null
        },
        {
            "name": "increased international normalized ratio",
            "percent": null
        },
        {
            "name": "INR",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        }
    ]
}